PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY

这项第一阶段研究的主要目的是评价其药理作用。 一种新开发的磁共振造影剂的剂量相关效应。 目前正在使用的试剂的剂量为0.1至0.3 mmol/kg。 这种新试剂是一种非离子的、胞外的、线性的Gd基试剂 将以0.1、0.3和0.5 mmol/kg的剂量进行测试的螯合物。 受试者将是已知的脑、脊柱和/或肝脏疾病的患者， 并被选为代表患者类型的代表 目前正在使用对比磁共振成像。 这项研究已于1997年9月完成。

The primary aim of this Phase I study is to evaluate the pharmacological dose-related effects of a newly developed contrast agent for use with MRI. Agents currently being used are available in doses of 0.1 to 0.3 mmol/kg. This new agent is a non-ionic, extracellular, linear gadolinium based chelate that will be tested in doses of 0.1, 0.3, and 0.5 mmol/kg. Subjects will be patients with known brain, spine, and/or liver disease, and were chosen to be representative of the type of patient for which contrast MRI is currently being used. This study was completed in September, 1997.